Araştırma Makalesi
BibTex RIS Kaynak Göster
Yıl 2024, , 366 - 372, 30.10.2024
https://doi.org/10.5472/marumj.1573453

Öz

Kaynakça

  • Galar A, Weil AA, Dudzinski DM, Muñoz P, Siedner MJ. Methicillin- Resistant Staphylococcus aureus Prosthetic Valve Endocarditis: Pathophysiology, Epidemiology, Clinical Presentation, Diagnosis, and Management. Clin Microbiol Rev. 2019 Mar 20;32(2). doi: 10.1128/CMR.00041- 18.
  • Abdulhak AAB, Baddour LM, Erwin PJ, et al. Global and regional burden of infective endocarditis, 1990–2010: a systematic review of the literature. Glob Heart. 2014;9(1):131– 43. doi: 10.1016/j.gheart.2014.01.002
  • Correa de Sa DD, Tleyjeh IM, Anavekar NS, et al. Epidemiological trends of infective endocarditis: a populationbased study in Olmsted County, Minnesota. Mayo Clin Proc. 2010 May;85(5):422-6. doi: 10.4065/mcp.2009.0585.
  • Nishimura RA, Otto CM, Bonow RO, et al. 2014 AHA/ ACC guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2014; 63:e57–185. doi: 10.1016/j.jacc.2014.02.536.
  • Cahill TJ, Prendergast BD. Infective endocarditis. Lancet. 2016 Feb 27;387(10021):882-93. doi: 10.1016/S0140- 6736(15)00067-7.
  • Sunder S, Grammatico-Guillon L, Baron S, et al. Clinical and economic outcomes of infective endocarditis. Infect Dis (Lond). 2015 Feb;47(2):80-7. doi: 10.3109/00365.548.2014.968608.
  • Alagna L, Park LP, Nicholson BP, et al. Repeat endocarditis: analysis of risk factors based on the International Collaboration on Endocarditis – Prospective Cohort Study. Clin Microbiol Infect. 2014 Jun;20(6):566-75. doi: 10.1111/1469-0691.12395.
  • Alkhouli M, Alqahtani F, Alhajji M, Berzingi CO, Sohail MR. Clinical and Economic Burden of Hospitalizations for Infective Endocarditis in the United States. Mayo Clin Proc. 2020 May;95(5):858-866. doi: 10.1016/j.mayocp.2019.08.023.
  • Li JS, Sexton DJ, Mick N, et al. Proposed modifications to the Duke criteria for the diagnosis of infective endocarditis. Clin Infect Dis. 2000 Apr;30(4):633-8. doi: 10.1086/313753.
  • Habib G, Lancellotti P, Antunes MJ, et al.; 2015 ESC Guidelines for the management of infective endocarditis: Eur Heart J. 2015 Nov 21;36(44):3075-3128. doi: 10.1093/eurheartj/ehv319.
  • Baddour LM, Wilson WR, Bayer AS, et al. Infective endocarditis in adults: diagnosis, antimicrobial therapy, and management of complications: a scientific statement for healthcare professionals from the American Heart Association. Circulation 2015; 132(15):1435e86. doi; 10.1161/ CIR.000.000.0000000296.
  • Henriquez E, Fatima N, Sayabugari R, et al. Transesophageal Echocardiography vs. Transthoracic Echocardiography for Methicillin-Sensitive Staphylococcus aureus and Methicillin- Resistant Staphylococcus aureus Endocarditis. Cureus. 2023 Jun 5;15(6):e39996. doi: 10.7759/cureus.39996.
  • Tahon J, Geselle PJ, Vandenberk B, et al. Long-term follow-up of patients with infective endocarditis in a tertiary referral center. Int J Cardiol. 2021 May 15;331:176-182. doi: 10.1016/j. ijcard.2021.01.048.
  • Silaschi M, Nicou N, Deshpande R, et al. Complicated infective aortic endocarditis: comparison of different surgical strategies. Interact Cardiovasc Thorac Surg. 2017 Sep 1;25(3):343-349. doi: 10.1093/icvts/ivx109.
  • Heiro M, Helenius H, Hurme S, et al. Long-term outcome of infective endocarditis: a study on patients surviving over one year after the initial episode treated in a Finnish teaching hospital during 25 years. BMC Infect Dis. 2008 Apr 17;8:49. doi: 10.1186/1471-2334-8-49.
  • Freitas-Ferraz AB, Tirado-Conte G, Vilacosta I, et al. Contemporary epidemiology and outcomes in recurrent infective endocarditis. Heart. 2020 Apr;106(8):596-602. doi: 10.1136/heartjnl-2019-315433.
  • Thornhill MH, Jones S, Prendergast B, et al. Quantifying infective endocarditis risk in patients with predisposing cardiac conditions. Eur Heart J. 2018 Feb 14;39(7):586- 595. doi: 10.1093/eurheartj/ehx655.
  • Fernández-Hidalgo N, Almirante B, Tornos P, et al. Contemporary epidemiology and prognosis of health careassociated infective endocarditis. Clin Infect Dis. 2008 Nov 15;47(10):1287-97. doi: 10.1086/592576.
  • Lawrence CHD, Cheaveau J, Kavourides M, Chadwick D, McCarron B. Endocarditis and the impact of intravenous drug use: a cohort study. Infect Dis (Lond). 2021 Oct;53(10):772- 778. doi: 10.1080/23744.235.2021.1928279
  • Huuskonen A, Kesävuori R, Raivio P. Outcomes after Surgery for Endocarditis among Intravenous Drug Users and Nonusers. Thorac Cardiovasc Surg. 2023 Jan;71(1):38-45. doi: 10.1055/s-0041.172.7231.
  • Fabri J Jr, Issa VS, Pomerantzeff PM, Grinberg M, Barretto AC, Mansur AJ. Time- related distribution, risk factors and prognostic influence of embolism in patients with left-sided infective endocarditis. Int J Cardiol. 2006 Jun 28;110(3):334-9. doi: 10.1016/j.ijcard.2005.07.016.
  • Lovelock T, Zhu MZL, Saran A, Vasudevan T. Embolic phenomena to the limbs are an independent predictor of inhospital mortality from infective endocarditis. ANZ J Surg. 2022 Sep;92(9):2312-17. doi: 10.1111/ans.17907.
  • Delahaye F, Alla F, Béguinot I, et al.; AEPEI Group. Inhospital mortality of infective endocarditis: prognostic factors and evolution over an 8-year period. Scand J Infect Dis. 2007;39(10):849-57. doi: 10.1080/003.655.40701393088.
  • Gelsomino S, Maessen JG, van der Veen F, et al. Emergency surgery for native mitral valve endocarditis: the impact of septic and cardiogenic shock. Ann Thorac Surg. 2012 May;93(5):1469-76. doi: 10.1016/j.athoracsur.2011.11.025.
  • Shiue AB, Stancoven AB, Purcell JB, et al. Relation of level of B-type natriuretic peptide with outcomes in patients with infective endocarditis. Am J Cardiol. 2010 Oct 1;106(7):1011- 5. doi: 10.1016/j.amjcard.2010.05.034.
  • Miro JM, Anguera I, Cabell CH, et al.; International Collaboration on Endocarditis Merged Database Study Group. Staphylococcus aureus native valve infective endocarditis: report of 566 episodes from the International Collaboration on Endocarditis Merged Database. Clin Infect Dis. 2005 Aug 15;41(4):507-14. doi: 10.1086/431979.
  • Ferrera C, Vilacosta I, Fernández C, et al. Reassessment of blood culture-negative endocarditis: its profile is similar to that of blood culture-positive endocarditis. Rev Esp Cardiol (Engl Ed). 2012 Oct;65(10):891-900. English, Spanish. doi: 10.1016/j.recesp.2012.04.004.
  • Castillo JC, Anguita MP, Ramírez A, et al. Long term outcome of infective endocarditis in patients who were not drug addicts: a 10 year study. Heart. 2000 May;83(5):525-30. doi: 10.1136/heart.83.5.525
  • Cabell CH, Jollis JG, Peterson GE, et al. Changing patient characteristics and the effect on mortality in endocarditis. Arch Intern Med. 2002 Jan 14;162(1):90-4. doi: 10.1001/ archinte.162.1.90.
  • Botelho-Nevers E, Thuny F, Casalta JP, et al. Dramatic reduction in infective endocarditis-related mortality with a management-based approach. Arch Intern Med. 2009 Jul 27;169(14):1290-8. doi: 10.1001/archinternmed.2009.192.
  • Ting SW, Chen JJ, Lee TH, Kuo G. Surgical versusmedical treatment for infective endocarditis in patients on dialysis: a systematic review and meta-analysis. Ren Fail. 2022 Dec;44(1):706-713. doi: 10.1080/0886022X.2022.206.4756.

Long-term follow-up of infective endocarditis: Rates of reinfection, mortality, and predictors of outcome

Yıl 2024, , 366 - 372, 30.10.2024
https://doi.org/10.5472/marumj.1573453

Öz

Objective: Infective endocarditis (IE) is a severe condition characterized by high mortality rates. We aimed to assess reinfection and
mortality rates in IE patients at a tertiary referral center during long-term follow-up.
Patients and Methods: We retrospectively analyzed 204 patients meeting modified Duke criteria for definite IE between 2009 and 2019.
Early reinfection was defined as occurrence within 6 months, and late reinfection was defined as occurrence 6 months after the initial
diagnosis.
Results: Mean follow-up duration was 40.3 ± 26.4 months. Valve surgery was performed in 125 patients (69.8%), while 54 (30.2%)
received medical therapy alone. Early reinfection was
seen in 9 patients (5.1%), and late reinfection in 12 patients (6.7%). Staphylococci (41.9%), Streptococci (26.3%), and Enterococci
(15.6%) were common pathogens. Peripheral limb emboli predicted reinfection (HR 4.118, 95% CI 1.471-11.528, p=0.007). Survival
rates at 1, 2, and 5 years were 70.2%, 65.7%, and 57.3%, respectively. Age (HR 1.030, 95% CI 1.011 – 1.049, p=0.002), peripheral limb
emboli (HR 2.994, 95% CI 1.509-5.940, p=0.002), and septic shock (HR 2.357, 95% CI 1.097-5.065, p=0.028) predicted mortality.
Conclusion: Infective endocarditis mortality rates remain high regardless of reinfection. Peripheral limb emboli independently
determine reinfection and mortality. Careful management of this group may reduce morbidity and mortality.

Kaynakça

  • Galar A, Weil AA, Dudzinski DM, Muñoz P, Siedner MJ. Methicillin- Resistant Staphylococcus aureus Prosthetic Valve Endocarditis: Pathophysiology, Epidemiology, Clinical Presentation, Diagnosis, and Management. Clin Microbiol Rev. 2019 Mar 20;32(2). doi: 10.1128/CMR.00041- 18.
  • Abdulhak AAB, Baddour LM, Erwin PJ, et al. Global and regional burden of infective endocarditis, 1990–2010: a systematic review of the literature. Glob Heart. 2014;9(1):131– 43. doi: 10.1016/j.gheart.2014.01.002
  • Correa de Sa DD, Tleyjeh IM, Anavekar NS, et al. Epidemiological trends of infective endocarditis: a populationbased study in Olmsted County, Minnesota. Mayo Clin Proc. 2010 May;85(5):422-6. doi: 10.4065/mcp.2009.0585.
  • Nishimura RA, Otto CM, Bonow RO, et al. 2014 AHA/ ACC guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2014; 63:e57–185. doi: 10.1016/j.jacc.2014.02.536.
  • Cahill TJ, Prendergast BD. Infective endocarditis. Lancet. 2016 Feb 27;387(10021):882-93. doi: 10.1016/S0140- 6736(15)00067-7.
  • Sunder S, Grammatico-Guillon L, Baron S, et al. Clinical and economic outcomes of infective endocarditis. Infect Dis (Lond). 2015 Feb;47(2):80-7. doi: 10.3109/00365.548.2014.968608.
  • Alagna L, Park LP, Nicholson BP, et al. Repeat endocarditis: analysis of risk factors based on the International Collaboration on Endocarditis – Prospective Cohort Study. Clin Microbiol Infect. 2014 Jun;20(6):566-75. doi: 10.1111/1469-0691.12395.
  • Alkhouli M, Alqahtani F, Alhajji M, Berzingi CO, Sohail MR. Clinical and Economic Burden of Hospitalizations for Infective Endocarditis in the United States. Mayo Clin Proc. 2020 May;95(5):858-866. doi: 10.1016/j.mayocp.2019.08.023.
  • Li JS, Sexton DJ, Mick N, et al. Proposed modifications to the Duke criteria for the diagnosis of infective endocarditis. Clin Infect Dis. 2000 Apr;30(4):633-8. doi: 10.1086/313753.
  • Habib G, Lancellotti P, Antunes MJ, et al.; 2015 ESC Guidelines for the management of infective endocarditis: Eur Heart J. 2015 Nov 21;36(44):3075-3128. doi: 10.1093/eurheartj/ehv319.
  • Baddour LM, Wilson WR, Bayer AS, et al. Infective endocarditis in adults: diagnosis, antimicrobial therapy, and management of complications: a scientific statement for healthcare professionals from the American Heart Association. Circulation 2015; 132(15):1435e86. doi; 10.1161/ CIR.000.000.0000000296.
  • Henriquez E, Fatima N, Sayabugari R, et al. Transesophageal Echocardiography vs. Transthoracic Echocardiography for Methicillin-Sensitive Staphylococcus aureus and Methicillin- Resistant Staphylococcus aureus Endocarditis. Cureus. 2023 Jun 5;15(6):e39996. doi: 10.7759/cureus.39996.
  • Tahon J, Geselle PJ, Vandenberk B, et al. Long-term follow-up of patients with infective endocarditis in a tertiary referral center. Int J Cardiol. 2021 May 15;331:176-182. doi: 10.1016/j. ijcard.2021.01.048.
  • Silaschi M, Nicou N, Deshpande R, et al. Complicated infective aortic endocarditis: comparison of different surgical strategies. Interact Cardiovasc Thorac Surg. 2017 Sep 1;25(3):343-349. doi: 10.1093/icvts/ivx109.
  • Heiro M, Helenius H, Hurme S, et al. Long-term outcome of infective endocarditis: a study on patients surviving over one year after the initial episode treated in a Finnish teaching hospital during 25 years. BMC Infect Dis. 2008 Apr 17;8:49. doi: 10.1186/1471-2334-8-49.
  • Freitas-Ferraz AB, Tirado-Conte G, Vilacosta I, et al. Contemporary epidemiology and outcomes in recurrent infective endocarditis. Heart. 2020 Apr;106(8):596-602. doi: 10.1136/heartjnl-2019-315433.
  • Thornhill MH, Jones S, Prendergast B, et al. Quantifying infective endocarditis risk in patients with predisposing cardiac conditions. Eur Heart J. 2018 Feb 14;39(7):586- 595. doi: 10.1093/eurheartj/ehx655.
  • Fernández-Hidalgo N, Almirante B, Tornos P, et al. Contemporary epidemiology and prognosis of health careassociated infective endocarditis. Clin Infect Dis. 2008 Nov 15;47(10):1287-97. doi: 10.1086/592576.
  • Lawrence CHD, Cheaveau J, Kavourides M, Chadwick D, McCarron B. Endocarditis and the impact of intravenous drug use: a cohort study. Infect Dis (Lond). 2021 Oct;53(10):772- 778. doi: 10.1080/23744.235.2021.1928279
  • Huuskonen A, Kesävuori R, Raivio P. Outcomes after Surgery for Endocarditis among Intravenous Drug Users and Nonusers. Thorac Cardiovasc Surg. 2023 Jan;71(1):38-45. doi: 10.1055/s-0041.172.7231.
  • Fabri J Jr, Issa VS, Pomerantzeff PM, Grinberg M, Barretto AC, Mansur AJ. Time- related distribution, risk factors and prognostic influence of embolism in patients with left-sided infective endocarditis. Int J Cardiol. 2006 Jun 28;110(3):334-9. doi: 10.1016/j.ijcard.2005.07.016.
  • Lovelock T, Zhu MZL, Saran A, Vasudevan T. Embolic phenomena to the limbs are an independent predictor of inhospital mortality from infective endocarditis. ANZ J Surg. 2022 Sep;92(9):2312-17. doi: 10.1111/ans.17907.
  • Delahaye F, Alla F, Béguinot I, et al.; AEPEI Group. Inhospital mortality of infective endocarditis: prognostic factors and evolution over an 8-year period. Scand J Infect Dis. 2007;39(10):849-57. doi: 10.1080/003.655.40701393088.
  • Gelsomino S, Maessen JG, van der Veen F, et al. Emergency surgery for native mitral valve endocarditis: the impact of septic and cardiogenic shock. Ann Thorac Surg. 2012 May;93(5):1469-76. doi: 10.1016/j.athoracsur.2011.11.025.
  • Shiue AB, Stancoven AB, Purcell JB, et al. Relation of level of B-type natriuretic peptide with outcomes in patients with infective endocarditis. Am J Cardiol. 2010 Oct 1;106(7):1011- 5. doi: 10.1016/j.amjcard.2010.05.034.
  • Miro JM, Anguera I, Cabell CH, et al.; International Collaboration on Endocarditis Merged Database Study Group. Staphylococcus aureus native valve infective endocarditis: report of 566 episodes from the International Collaboration on Endocarditis Merged Database. Clin Infect Dis. 2005 Aug 15;41(4):507-14. doi: 10.1086/431979.
  • Ferrera C, Vilacosta I, Fernández C, et al. Reassessment of blood culture-negative endocarditis: its profile is similar to that of blood culture-positive endocarditis. Rev Esp Cardiol (Engl Ed). 2012 Oct;65(10):891-900. English, Spanish. doi: 10.1016/j.recesp.2012.04.004.
  • Castillo JC, Anguita MP, Ramírez A, et al. Long term outcome of infective endocarditis in patients who were not drug addicts: a 10 year study. Heart. 2000 May;83(5):525-30. doi: 10.1136/heart.83.5.525
  • Cabell CH, Jollis JG, Peterson GE, et al. Changing patient characteristics and the effect on mortality in endocarditis. Arch Intern Med. 2002 Jan 14;162(1):90-4. doi: 10.1001/ archinte.162.1.90.
  • Botelho-Nevers E, Thuny F, Casalta JP, et al. Dramatic reduction in infective endocarditis-related mortality with a management-based approach. Arch Intern Med. 2009 Jul 27;169(14):1290-8. doi: 10.1001/archinternmed.2009.192.
  • Ting SW, Chen JJ, Lee TH, Kuo G. Surgical versusmedical treatment for infective endocarditis in patients on dialysis: a systematic review and meta-analysis. Ren Fail. 2022 Dec;44(1):706-713. doi: 10.1080/0886022X.2022.206.4756.
Toplam 31 adet kaynakça vardır.

Ayrıntılar

Birincil Dil İngilizce
Konular Cerrahi (Diğer)
Bölüm Original Research
Yazarlar

Mehmet Altunova 0000-0001-5351-5022

Recep Gülmez Bu kişi benim 0000-0002-9956-8338

Hicaz Zincirkiran Ağuş Bu kişi benim 0000-0002-5882-0525

Tugba Aktemur 0000-0002-5578-432X

Serpil Öztürk 0000-0002-1967-6401

Ali Evsen 0000-0002-3780-7137

Yusuf Demir Bu kişi benim 0000-0001-9167-493X

Uğur Köktürk 0000-0003-0459-9295

Mehmet Köseoğlu 0000-0002-5138-6367

Gamze Babur Güler 0000-0003-1207-8692

Yayımlanma Tarihi 30 Ekim 2024
Gönderilme Tarihi 1 Mart 2024
Kabul Tarihi 15 Mayıs 2024
Yayımlandığı Sayı Yıl 2024

Kaynak Göster

APA Altunova, M., Gülmez, R., Zincirkiran Ağuş, H., Aktemur, T., vd. (2024). Long-term follow-up of infective endocarditis: Rates of reinfection, mortality, and predictors of outcome. Marmara Medical Journal, 37(3), 366-372. https://doi.org/10.5472/marumj.1573453
AMA Altunova M, Gülmez R, Zincirkiran Ağuş H, Aktemur T, Öztürk S, Evsen A, Demir Y, Köktürk U, Köseoğlu M, Babur Güler G. Long-term follow-up of infective endocarditis: Rates of reinfection, mortality, and predictors of outcome. Marmara Med J. Ekim 2024;37(3):366-372. doi:10.5472/marumj.1573453
Chicago Altunova, Mehmet, Recep Gülmez, Hicaz Zincirkiran Ağuş, Tugba Aktemur, Serpil Öztürk, Ali Evsen, Yusuf Demir, Uğur Köktürk, Mehmet Köseoğlu, ve Gamze Babur Güler. “Long-Term Follow-up of Infective Endocarditis: Rates of Reinfection, Mortality, and Predictors of Outcome”. Marmara Medical Journal 37, sy. 3 (Ekim 2024): 366-72. https://doi.org/10.5472/marumj.1573453.
EndNote Altunova M, Gülmez R, Zincirkiran Ağuş H, Aktemur T, Öztürk S, Evsen A, Demir Y, Köktürk U, Köseoğlu M, Babur Güler G (01 Ekim 2024) Long-term follow-up of infective endocarditis: Rates of reinfection, mortality, and predictors of outcome. Marmara Medical Journal 37 3 366–372.
IEEE M. Altunova, “Long-term follow-up of infective endocarditis: Rates of reinfection, mortality, and predictors of outcome”, Marmara Med J, c. 37, sy. 3, ss. 366–372, 2024, doi: 10.5472/marumj.1573453.
ISNAD Altunova, Mehmet vd. “Long-Term Follow-up of Infective Endocarditis: Rates of Reinfection, Mortality, and Predictors of Outcome”. Marmara Medical Journal 37/3 (Ekim 2024), 366-372. https://doi.org/10.5472/marumj.1573453.
JAMA Altunova M, Gülmez R, Zincirkiran Ağuş H, Aktemur T, Öztürk S, Evsen A, Demir Y, Köktürk U, Köseoğlu M, Babur Güler G. Long-term follow-up of infective endocarditis: Rates of reinfection, mortality, and predictors of outcome. Marmara Med J. 2024;37:366–372.
MLA Altunova, Mehmet vd. “Long-Term Follow-up of Infective Endocarditis: Rates of Reinfection, Mortality, and Predictors of Outcome”. Marmara Medical Journal, c. 37, sy. 3, 2024, ss. 366-72, doi:10.5472/marumj.1573453.
Vancouver Altunova M, Gülmez R, Zincirkiran Ağuş H, Aktemur T, Öztürk S, Evsen A, Demir Y, Köktürk U, Köseoğlu M, Babur Güler G. Long-term follow-up of infective endocarditis: Rates of reinfection, mortality, and predictors of outcome. Marmara Med J. 2024;37(3):366-72.